Celyad announces initiation of the SHRINK trial

Celyad announces initiation of the SHRINK trial

Celyad publishes additional pre-clinical data in support of THINK trial

Celyad publishes additional pre-clinical data in support of THINK trial

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells

Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells

Discover our news

Upcoming events

Aug 21-25, 2017

Bioprocessing summit

Sep 19-21, 2017

Phacilitate Europe

Discover all events

Press contacts

Celyad

Nicolas Van Hoecke
Director, Investor Relations & Communications

+32 (0)10 39 41 84

Stern Investor Relations (US)

Will O’Connor, Michael Schaffzin

+1 212 362 1200

Consilium Strategic Communications (UK)

Chris Welsh, Chris Gardner

+44 20 3709 5700

NewCap (France)

Nicolas Merigeau, Pierre Laurent

+ 33(0)1 44 71 94 94

Comfi (Belgium)

Gunther De Backer, Sabine Leclercq

+32(0) 2 290 90 91